Mylan Announces Voluntary De-listing Of 1.25% Senior Convertible Notes Due 2012 From Nasdaq
PITTSBURGH, Jan. 5, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has notified The Nasdaq Stock Market, an exchange of the NASDAQ OMX Group Inc. (Nasdaq: NDAQ), that it intends to voluntarily de-list its 1.25% Senior Convertible Notes due 2012 from the Nasdaq Capital Market, on which the notes trade under the ticker symbol "MYLNG," effective as of the open of trading on January 28, 2011. The notes will continue to trade over-the-counter (OTC) with trade data available through the Financial Industry Regulatory Authority's Trade Reporting and Compliance Engine ("TRACE"). Moving the trading of the notes from Nasdaq to the OTC market will bring the company in line with standard capital markets practice and reduce the company's regulatory burden.
On January 5, 2011, Nasdaq notified the company that the notes did not have the number of market makers required by Nasdaq's continued listing standards. While there are multiple securities firms that regularly trade the notes, these firms do not meet the strict criteria required of a market maker under Nasdaq's listing standards. The de-listing of the notes from Nasdaq does not affect the listing or trading of the company's common stock, ticker symbol "MYL," which will continue uninterrupted on Nasdaq.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.
SOURCE Mylan Inc.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
